

Finally, no compromise in the management of your STEMI patients

Acute care in STEMI

- ▶ Thrombolysis and aspirin superior to supportive care (ISIS-2, GISSI)¹
- ▶ Timely primary PCI superior to thrombolysis² (no benefit of facilitated PCI³)
- ▶ BMS superior to balloon angioplasty⁴
- ▶ Drug eluting stents (DES) are preferred to bare metal stents (BMS)^{5,6}
- ▶ Does the choice of DES matter? YES⁶


▶ DES versus BMS for STEMI

- ▶ Trials with first generation DES versus BMS had suggested that while DES reduced target lesion revascularisation (TLR), mortality was similar and there were safety concerns with possible increased rates of very late stent thrombosis and re-infarction⁷
- ▶ Trials with second generation DES show advantage of DES in terms of efficacy but only similar safety outcomes⁸
- ▶ BioMatrix family - 3rd generation DES with Biolimus A9 (BA9™) and a biodegradable polymer combines the efficacy of DES with a safety profile superior to BMS^{6,9,10}

BioMatrix™ Family in STEMI - BA9™ eluting stents (BES) with biodegradable polymer

- ▶ STEMI subset from LEADERS shows clear advantages of BES over SES

- ▶ COMFORTABLE-AMI is the first randomised clinical trial that demonstrates the superiority of a DES over BMS in terms of safety in STEMI patients^{6,9,10}



*All p-values are for superiority

1. Bagent C L et al., ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group., *BMJ*. 1998 May 2;316(7141):1337-43.
2. Grines C L et al., A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group, *N Engl J Med*. 1993 Mar 11;328(10):673-679.
3. Keeley E C et al., Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomized trials, *the Lancet*, 2006 Feb 18;367(9510):579-588.
4. De Luca G et al., Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials, *Int J Cardiol*. 2008 May 7;126(1):37-44.
5. Steg PG et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, *Eur Heart J*. 2012 Oct;33(20):2569-619.
6. Raeber L et al., Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial, *JAMA*. 2012 Aug 22;308(8):777-87.
7. De Luca G et al., Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials, *Arch Intern Med*. 2012 Apr 23;172(8):611-21.
8. Sabate M et al., Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomized controlled trial, *the Lancet*, 2012 Oct 27;380(9852):1482-90.
9. Raeber L, Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: the COMFORTABLE AMI trial, *EuroPCR 2012*, from late breaking trials to clinical practice.
10. Raeber L, Biolimus-eluting stents with biodegradable polymer versus bare metal stents in acute myocardial infarction: two year clinical follow-up and results of serial multimodality imaging (OCT/IVUS) The COMFORTABLE AMI-HBIS 4 trial, *EUROPCR 2013*, Hot line - trial updates and registries.

COMFORTABLE AMI – Clinical Trials Unit, Bern University Hospital, Bern, Switzerland. Supported by Biosensors. NCT00962416

BioMatrix family, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd.

Not available for sale in the United States and certain other countries.

© 2013 Biosensors International Group, Ltd. All rights reserved.

www.biosensors.com



BIOSENSORS EUROPE SA

Rue de Lausanne 29
1110 Morges
Switzerland
Tel: +41 (0)21 804 80 000
Fax: +41 (0)21 804 80 01

BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD

Blk 10 Kaki Bukit Avenue 1
#06-01/04
Singapore 417942
Tel: +65 6213 5725
Fax: +65 6213 5737